HelixNano's mRNA vaccines combine two patented functions: a zoom function directing antibodies at a conserved site on the spike protein, and an amplify function multiplying the immune response roughly one hundredfold. The design targets mutation resistance across variants rather than strain-specific protection.
Delivery uses room-temperature skin-applied mRNA developed with the Louis Falo laboratory at the University of Pittsburgh. The format deploys as simply as adhesive bandages, removing cold-chain dependence for global immunization.
HelixNano targets second-generation broadly protective boosters for global immunization, serving populations where larger vaccine makers underinvest. Room-temperature delivery and mutation-resistant design position the platform for equitable worldwide deployment.
The same manufacturing engine extends the addressable market into personalized cancer vaccines via rapid mRNA production. Success in infectious disease would validate a platform spanning pandemic response and precision oncology.
Helix Nanotechnologies pursues cheap treatments, decentralized progress, and biology modifiable at the push of a button. Its platform compresses experiments from months or years to weeks, and from millions of dollars to thousands.
The company is moving its COVID candidate for immunocompromised patients toward the clinic while testing environmental intervention concepts. The same rapid-manufacture mRNA engine spins back toward personalized cancer vaccines.
